GPLD1

Across TCGA pan-cancer cohorts, GPLD1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPLD1 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GPLD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GPLD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, UCEC, and GBM are the cancer types where GPLD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.866	0.623	.004	45	view →
UCEC	DFS	Tertile	III,IV	0.256	1.000	.002	28	view →
GBM	DFS	Median	All	0.528	0.233	.001	14	view →
LUAD	OS	Tertile	III,IV	0.261	0.839	.002	13	view →
HNSC	DFS	Median	All	0.860	0.361	.022	7	view →
LSCC	OS	Median	All	0.918	1.000	.007	7	view →
PDAC	OS	Tertile	All	0.694	0.956	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPLD1–CCRCC (DFS)

Open the CCRCC breakdown →